Press Release Resideo Announces Fourth Quarter and Full Year 2025 Financial Results and Initiates 2026 Outlook
Press Release Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
